Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

U.S. stock indexes inched their way to more records Monday to kick off a week full of profit updates from big U.S. companies.

U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S. companies. The S&P 500 rose 0.1% and squeaked past its prior all-time high set on ...

U.S. stock indexes inched to more records to kick off a week full of profit updates from big U.S. companies. The S&P 500 rose ...

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient ...

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk. The Food and Drug Administration will request that the company voluntarily ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died.